Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Patients with
hepatocellular carcinoma
(
HCC
) have a poor prognosis, and novel molecular targets for treating recurrence and progression of the disease along with associated biomarkers are urgently required. In the present study, expression and the regulatory mechanism of
TUSC1
(
tumor suppressor candidate 1
) were investigated to determine if it is a candidate tumor suppressor gene for
HCC
, which shows repressed transcription that involves aberrant DNA methylation.
TUSC1
mRNA expression levels in
HCC
cell lines and 94 pairs of surgical specimens were determined using quantitative real-time reverse transcription polymerase chain reaction assay. Methylation status of
HCC
cell lines and clinical samples were analyzed to investigate the regulatory mechanism of
TUSC1
transcription and the relationship between the methylation status of the
TUSC1
gene and clinicopathological factors. The expression and distribution of the
TUSC1 protein
in liver tissues were determined using immunohistochemistry. A majority of
HCC
cell lines (89%) and surgical specimens (84%) demonstrated reduced expression levels of
TUSC1
mRNA compared with paired non-cancerous liver tissues. The mean mRNA expression level in
HCC
was significantly lower than in corresponding non-cancerous liver. In contrast, no significant difference was found in
TUSC1
mRNA expression level between adjacent normal and cirrhotic liver tissue from
HCC
patients. The
TUSC1 protein
expression pattern in
HCC
and liver tissues was consistent with
TUSC1
mRNA expression. Twenty-nine (31%) of 94 patients showed intragenic hypermethylation of the
TUSC1
gene in
HCC
, and hypermethylation was significantly associated with advanced pathological stage. Subsequently, patients with hypermethylation of the
TUSC1
gene had a significantly poorer prognosis than patients without hypermethylation. Our results suggest that
TUSC1
is a candidate tumor suppressor gene and intragenic hypermethylation is one of the suppressive mechanisms that regulate
TUSC1
transcription in
HCC
. Intragenic methylation of the
TUSC1
gene may serve as a novel prognostic marker of
HCC
.
...
PMID:Identification of intragenic methylation in the TUSC1 gene as a novel prognostic marker of hepatocellular carcinoma. 2436